ERBB2 and neoplasm: They isolated tumor cells based on their surface marker expression levels on the anti-EpCAM antibody-coated chip and anti-HER2 antibody-coated chip and achieved capture efficiencies of 98.91% for EpCAM+ cells and 86.51% for HER2+ cells, respectively, with 22% purity, at high throughput (24 mL/h).